世界中医药
世界中醫藥
세계중의약
WORLD CHINESE MEDICINE
2013年
10期
1202-1204
,共3页
康晓黎%王颖杰%夏廷毅%邸玉鹏%李宏奇%范乃斌%吴伟章
康曉黎%王穎傑%夏廷毅%邸玉鵬%李宏奇%範迺斌%吳偉章
강효려%왕영걸%하정의%저옥붕%리굉기%범내빈%오위장
局部晚期不可手术的胰腺癌%靶中靶放射治疗%放化疗%乌梅丸%康艾注射液
跼部晚期不可手術的胰腺癌%靶中靶放射治療%放化療%烏梅汍%康艾註射液
국부만기불가수술적이선암%파중파방사치료%방화료%오매환%강애주사액
Inoperable advanced pancreatic cancer%Target in target radiation therapy%Chemoradiotherapy%Wu Mei Wan%Kangai in-jection
目的：观察评价中药联合靶中靶放射治疗局部晚期不可手术的胰腺癌的疗效和放射治疗副反应。方法：对我院自2008年10月至2011年12月采用中药联合靶中靶放射治疗的42例局部晚期不可手术的胰腺癌患者行回顾性分析。三维适形或调强放疗实现靶区剂量层层递增，单纯放疗29例，同步放化疗加中药乌梅丸加减治疗13例，所有患者均使用中药康艾注射液。结果：原发灶完全缓解率CR（12/42）28.6％、部分缓解率PR（20/42）47.6％，总有效率（ CR＋PR）为76.2％；全组中位生存时间和1年总生存率（ OS）分别为14.8个月和51.7％。同步化疗的加入较单放有提高生存的趋势但尚未达统计学意义（ P＝0.089）。放疗末总临床获益者31例，主要为腹痛缓解23例。不良反应主要表现为急性消化道反应。结论：康艾注射液联合靶中靶放射治疗局部晚期不可手术的胰腺癌采用靶区剂量层层递增的模式是安全有效的，毒副反应低，可提高临床获益。加同步化疗联合中药乌梅丸有提高生存率趋势。
目的：觀察評價中藥聯閤靶中靶放射治療跼部晚期不可手術的胰腺癌的療效和放射治療副反應。方法：對我院自2008年10月至2011年12月採用中藥聯閤靶中靶放射治療的42例跼部晚期不可手術的胰腺癌患者行迴顧性分析。三維適形或調彊放療實現靶區劑量層層遞增，單純放療29例，同步放化療加中藥烏梅汍加減治療13例，所有患者均使用中藥康艾註射液。結果：原髮竈完全緩解率CR（12/42）28.6％、部分緩解率PR（20/42）47.6％，總有效率（ CR＋PR）為76.2％；全組中位生存時間和1年總生存率（ OS）分彆為14.8箇月和51.7％。同步化療的加入較單放有提高生存的趨勢但尚未達統計學意義（ P＝0.089）。放療末總臨床穫益者31例，主要為腹痛緩解23例。不良反應主要錶現為急性消化道反應。結論：康艾註射液聯閤靶中靶放射治療跼部晚期不可手術的胰腺癌採用靶區劑量層層遞增的模式是安全有效的，毒副反應低，可提高臨床穫益。加同步化療聯閤中藥烏梅汍有提高生存率趨勢。
목적：관찰평개중약연합파중파방사치료국부만기불가수술적이선암적료효화방사치료부반응。방법：대아원자2008년10월지2011년12월채용중약연합파중파방사치료적42례국부만기불가수술적이선암환자행회고성분석。삼유괄형혹조강방료실현파구제량층층체증，단순방료29례，동보방화료가중약오매환가감치료13례，소유환자균사용중약강애주사액。결과：원발조완전완해솔CR（12/42）28.6％、부분완해솔PR（20/42）47.6％，총유효솔（ CR＋PR）위76.2％；전조중위생존시간화1년총생존솔（ OS）분별위14.8개월화51.7％。동보화료적가입교단방유제고생존적추세단상미체통계학의의（ P＝0.089）。방료말총림상획익자31례，주요위복통완해23례。불량반응주요표현위급성소화도반응。결론：강애주사액연합파중파방사치료국부만기불가수술적이선암채용파구제량층층체증적모식시안전유효적，독부반응저，가제고림상획익。가동보화료연합중약오매환유제고생존솔추세。
Objective:To evaluate the efficacy and side reactions of Traditional Chinese Medicine along with target in target radiation therapy in patients with inoperable advanced pancreatic cancer .Methods:Retrospective analysis was given to 42 patients with inopera-ble advanced pancreatic cancer admitted to our hospital from October 2000 to December 2012.Patients were treated with Kangai injec-tion and three-dimensional conformal radiation therapy (3D-CRT) or Intensity-modulated radiation therapy (IMRT).Low-speed compu-ted tomography simulation was conducted .Among these , thirteen patients received concurrent chemotherapy and modified Wu Mei Wan . Results:The complete response rate (CR) and the partial response rate (PR) in the primary tumors were 28.6%and 47.6%, and the overall response rate (CR+PR) was 76.2%.The median survival time (MST) and 1-year overall survival rate (OS) was 14.8 months and51.7%.Concurrent chemoradiotherapy tended to improve overall survival (P=0.089).After treatment, 31 patients had clinical benefit response , mainly abdominal pain relief .Conclusion:Kangai injection and target in target radiation therapy is effective in allevia-tion of disease-related symptoms in patients with inoperable pancreatic cancer , though concurrent chemoradiotherapy with Wu Mei Wan confers a trend of survival improvement over sole radiotherapy .
